

Healthy for Life

Decoding the biology of aging to treat age-related diseases

Rejuvenate Biomed is an AI-enabled clinical-stage biotech company developing safe oral combination therapeutics that alter the course of age-related diseases

RJx-01: Advancing muscle health - unlocking value in sarcopenia


- Excellent safety and tolerability in humans, with a differentiated pharmacokinetic profile
- Clinical efficacy: significant improvements in muscle strength, function, and fatigue resistance in humans
- Transformative mechanism of action: boosted mitochondrial energy, reduced inflammation, and reversed fibrosis – tackling root causes of age-related muscle decline

Pipeline powered by innovation

- CombinAge™ platform: proprietary AI-enabled discovery engine identified next-generation RJx-combinations for age-related diseases
- Robust pipeline: multiple preclinical assets available for partnering across high-value indications
- Clinical Phase 2b data inflection points for disease- and treatment-induced sarcopenia end 2026 and mid 2027 respectively
- Strong IP position

How we generate value

Harnessing **clinically validated**, AI-enabled and **in vivo platforms**, we discover novel combinations to alter the course of age-related diseases



We build a pipeline of 'ready to partner' **novel combination drugs** for multiple indications with new formulations and strong IP protection

Our pipeline

PROGRAM	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2
RJx-01	Disease-induced acute & chronic sarcopenia (COPD)			
RJx-01	Treatment-induced sarcopenia (obesity)			
RJx-02/06	Non-disclosed			

RJx-01 in Phase 2 clinical trials

- Disease-induced sarcopenia: Phase 2 trial **enrolling** COPD patients with sarcopenia; results expected end 2026
- Treatment-induced sarcopenia: Phase 2 trial **upcoming**: muscle health protection during obesity treatment; results mid 2027

Let's connect

info@rejuvenatebiomed.com
www.rejuvenatebiomed.com

Health Campus Limburg
3590 Diepenbeek
Belgium 

One Broadway
Cambridge, MA 02142
USA 

Three critical success factors



We start from **approved drugs with safety profiles** suitable for chronic use



We employ our clinically **validated proprietary AI** and **in vivo platforms**, CombinAge™ and CelegAge™



We secure **strong patent protection**, both composition and medical applications & formulation